Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings Of The Fortnight: Follow-On Fever

This article was originally published in The Pink Sheet Daily

Executive Summary

Does the recent rash of follow-on public offerings mean biotech IPOs are around the corner? Recent financings provide reason to think it's possible.

You may also be interested in...



VCs Must Get Back To Basics And Fund Innovation - MassBio Panel

Now that the "me too" era is over, venture capitalists should turn back to building innovative biotech companies, panelists at MassBio's annual meeting say.

VCs Must Get Back To Basics And Fund Innovation - MassBio Panel

Now that the "me too" era is over, venture capitalists should turn back to building innovative biotech companies, panelists at MassBio's annual meeting say.

Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel